Nilotinib is primarily used in the treatment of chronic myeloid leukemia (CML), specifically in patients who are either resistant or intolerant to imatinib, the first-generation TKI. Research is ongoing to evaluate its efficacy in other types of cancers, but its approval is currently limited to CML.
